Drug pricing

'What the Health?': The Drug Price Dilemma

Retrieved on: 
Friday, July 30, 2021
Health sciences, Health, Pharmaceutical industry, Pharmacy, Pharmaceuticals policy, Clinical pharmacology, Drug pricing, Medication costs, Medical prescription, Medication, Prescription drug, Prescription drug prices in the United States

That is because the dilemma faced by many Americans is the struggle of paying the price for filling their prescriptions.

Key Points: 
  • That is because the dilemma faced by many Americans is the struggle of paying the price for filling their prescriptions.
  • Among other G7 nations the UK, France, and Italy have the lowest prescription drug prices.
  • Canada's drug prices are higher, but still considerably less than the cost for the same medications in the USA.
  • That improved access has yet to be seen, and so the dilemma of figuring out ways to afford prescription medication continues for many Americans.

Optinose Announces Preliminary Second Quarter 2021 XHANCE Net Revenue of $18.4 Million

Retrieved on: 
Wednesday, July 28, 2021
Clinical pharmacology, Medical prescription, Patient safety, Symbols, Health, Pharmaceuticals policy, Drug pricing

YARDLEY, Pa., July 28, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced preliminary XHANCE® (fluticasone propionate) net product revenue of $18.4 million for the three months ended June 30, 2021. This represents a 79% increase compared to the three months ended June 30, 2020, and a 67% increase compared to the three months ended March 31, 2021. The Company expects XHANCE net product revenue for the full year of 2021 to be at least $80 million.

Key Points: 
  • The Company expects XHANCE net product revenue for the full year of 2021 to be at least $80 million.
  • In addition, the number of XHANCE prescriptions increased by 33% from 62,500 in the second quarter 2020 to 82,900 in the second quarter 2021 based on third-party prescription data and data from XHANCE preferred pharmacy network partners.
  • XHANCE net revenue per prescription increased 35% from $164 in the second quarter 2020 to $221 in the second quarter 2021 based on preliminary second quarter net product revenue of $18.4 million.
  • We are pleased with the growth in demand for XHANCE and increased net product revenue per prescription based on preliminary second quarter net product revenue of $18.4 million, stated CEO Peter Miller.

National Coalition on Health Care and West Health to Co-Host Congressional Briefing on Drug Pricing Reform

Retrieved on: 
Wednesday, July 28, 2021
Health, Articles, Drug pricing, Pharmaceutical industry, Health Economics, Medication costs, Pharmacy, Health equity

WASHINGTON, July 28, 2021 /PRNewswire/ -- On July 28 from 1-2pm ET the National Coalition on Health Care (NCHC) and West Health will co-host a second Congressional briefing titled Drug Pricing Reform: The Costs of Inaction .

Key Points: 
  • WASHINGTON, July 28, 2021 /PRNewswire/ -- On July 28 from 1-2pm ET the National Coalition on Health Care (NCHC) and West Health will co-host a second Congressional briefing titled Drug Pricing Reform: The Costs of Inaction .
  • Also, Amy Herr of West Health will present public opinion research on prescription drug prices, and Shawn Gremminger of Purchaser Business Group on Health will discuss the impact on employers.
  • The event will build on the first briefing , which highlighted how high drug prices, coverage gaps, and other systemic issues drive health inequities for communities of color.
  • The first briefing, The Burden of High Drug Prices Among Communities of Color, featured several prominent speakers and new data from West Health's survey on drug accessibility and affordability.

Caravan Health Offers New 340B Services for Medicare and Commercial Claims

Retrieved on: 
Tuesday, July 20, 2021
Health Resources and Services Administration, Healthcare reform in the United States, Drug pricing, Health, 340B Drug Pricing Program, Federal assistance in the United States, Presidency of Lyndon B. Johnson, Medicare

KANSAS CITY, Mo., July 20, 2021 /PRNewswire-PRWeb/ -- Today, Caravan Health announced a new line of business serving health care providers participating in the 340B drug discount program .

Key Points: 
  • KANSAS CITY, Mo., July 20, 2021 /PRNewswire-PRWeb/ -- Today, Caravan Health announced a new line of business serving health care providers participating in the 340B drug discount program .
  • This new offering will enable covered entities to get the most out of both Medicare and commercial prescription claims for all their patients, regardless of where prescriptions are filled.
  • By participating in 340B, safety-net providers can reach more eligible patients and provide more comprehensive services in their communities.
  • Caravan Health is a privately held company formed to create a sustainable model for health systems to excel in value-based payment models and the 340B drug discount program.

United States Pharmaceutical Drug Delivery Market Prospects, Trends Analysis, Market Size and Forecasts 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 14, 2021
Health, Pharmaceutical, Health sciences, Health care, Health, Pharmaceuticals policy, Pharmaceutical industry, Pharmacology, Pharmacy, Drug pricing, Pharmaceutical industry in China, Contract manufacturing organization

The "United States Pharmaceutical Drug Delivery Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Pharmaceutical Drug Delivery Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The country research report on the United States pharmaceutical drug delivery market is a customer intelligence and competitive study of the United States market.
  • The companies and dealers/distributors profiled in the report include manufacturers & suppliers of pharmaceutical drug delivery market in the United States.
  • 5) What are the modes of entering the United States pharmaceutical drug delivery market?

AACCNJ Launches Prescription Savings Solution to Provide Members with Better Pricing and Access to Medications

Retrieved on: 
Wednesday, July 7, 2021
Medicinal chemistry, Symbols, Pharmacies, Pharmaceuticals policy, Articles, Drug pricing

The AACCNJ-branded solution ensures low prices on medications at any pharmacy, regardless of insurance coverage.

Key Points: 
  • The AACCNJ-branded solution ensures low prices on medications at any pharmacy, regardless of insurance coverage.
  • AACCNJ is offeringaprescription savings solution to its membersand their employees as a perk of belonging to the chamber and a service to the community.
  • "By ensuring constituents and community members can affordably access medications that are central to maintaining their health, we are upholding our commitment to making life better for our members and the community as a whole."
  • The AACCNJ cash price card can be used at any pharmacy, including those that are out of network for a member's health plan.

Leading Drug Pricing Experts - Legacy Health Endowment and Powers Law - Collaborate on Series of Issue Papers: Initial Paper Focuses on Intersection of PBMs and the 340B Drug Pricing Program

Retrieved on: 
Tuesday, June 29, 2021
Drug pricing, Health sciences, Health Resources and Services Administration, Pharmacy, 340B Drug Pricing Program, Pharmaceutical sciences, Health care, Pharmacy benefit management, Pharmaceutical industry, Medication costs, Pricing

Few Americans are aware, however, that the federal 340B drug pricing program is already providing relief from high drug prices for safety net providers and the communities they serve.

Key Points: 
  • Few Americans are aware, however, that the federal 340B drug pricing program is already providing relief from high drug prices for safety net providers and the communities they serve.
  • Many people also do not know that the 340B program is under attack from both the drug manufacturers selling 340B drugs and the pharmacy benefit managers (PBMs) paying for them.
  • "The 340B program and PBMs are two inextricably linked pieces of the U.S. healthcare system," said Jeffrey Lewis, President, and CEO of Legacy Health Endowment.
  • The firm's drug pricing practice is led by William von Oehsen, one of the architects of the 340B program.

LowerMyRx Has Saved Patients Millions on Medication Purchases

Retrieved on: 
Thursday, June 24, 2021
Health sciences, Pharmaceutical industry, Pharmaceutical sciences, Health, Drug pricing, Pharmacy, Medication costs, Pharmaceuticals policy, Medication, Prescription drug prices in the United States

MOUNT LAUREL, N.J., June 24, 2021 /PRNewswire/ -- LowerMyRx, a nationwide prescription discount program, announced today that their free service has been able to save patients millions of dollars on medication purchases over the past eightyears.

Key Points: 
  • MOUNT LAUREL, N.J., June 24, 2021 /PRNewswire/ -- LowerMyRx, a nationwide prescription discount program, announced today that their free service has been able to save patients millions of dollars on medication purchases over the past eightyears.
  • LowerMyRx helps consumers search and compare discounted medication prices, saving patients up to 80% at thousands of pharmacies nationwide.
  • Whether it be blood pressure medication or cholesterol-lowering medication, patients can search for discounts on LowerMyRx.com and save.
  • Lowering medication costs since 2013, LowerMyRx strives to help as many patients as possible and make medication affordable for all.

AHF Joins Coalition Demanding Rx Price Negotiation in ‘Build Back Better’ Law

Retrieved on: 
Friday, June 18, 2021
AIDS, White House, Federal Government, Public policy, Government, Healthcare reform, Health, Pharmaceutical, Health sciences, Pharmaceutical industry, Pharmacy, Pharmaceutical sciences, Health, AIDS Healthcare Foundation, Drug pricing, AHF, Medication costs, Medication

AIDS Healthcare Foundation ( AHF ) joined over 103 labor unions and health care groups to demand the U.S. Congress include popular drug price reform in the so-called Build Back Better legislation to fund infrastructure spending.

Key Points: 
  • AIDS Healthcare Foundation ( AHF ) joined over 103 labor unions and health care groups to demand the U.S. Congress include popular drug price reform in the so-called Build Back Better legislation to fund infrastructure spending.
  • Hundreds of elected officials have campaigned on requiring the government to negotiate drug prices and provide protections for patients in need of affordable medicines.
  • The question is whether Congress will listen to drug company lobbyists or the people they took an oath to represent, said Hassell.
  • To learn more about AHF, please visit our website: www.aidshealth.org , find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210618005525/en/

Suggested Reasons for Price of Prescription Drugs in America

Retrieved on: 
Tuesday, June 1, 2021
Health sciences, Health, Pharmacy, Pharmaceuticals policy, Pharmaceutical industry, Drug pricing, Drugs, Medication costs, Prescription drug, Medication, Prescription drug prices in the United States, Draft:Altrui Foundation

High prescription medication costs are a harsh reality for the average American, and these days relief from paying high costs for life-saving medication is needed more than ever.

Key Points: 
  • High prescription medication costs are a harsh reality for the average American, and these days relief from paying high costs for life-saving medication is needed more than ever.
  • Big pharma always insists there are legitimate reasons why Rx medications are so expensive, but many of them aren't legitimized.
  • Although this holds to be true, profits generated from selling prescription medication cover for those costs and produce tidy profits.
  • In America, companies have patents on their pharmaceuticals, and while the patents are still in place, the prescription medications can be valued at whatever price point they think is best.